drugset / Trial / NCT05189535

"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

NCT05189535

Phase 2/3 Completed 66 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindPrevention

Summary

The aim of this study is to evaluate the effect of pentoxifylline 400 mg twice daily administration on the prevention of paclitaxel-Induced peripheral neuropathy in breast cancer patients.

Timeline

Start
2021-10-03
Primary completion
2023-09-18
Completion
2023-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 400 mg Oral
Background Paclitaxel Small molecule 80 mg/m2 Intravenous